PMS5 PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE (original) (raw)

Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss

Lisa Lix

Gastroenterology, 2010

View PDFchevron_right

Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

Hershel Jick

Pharmacotherapy, 2008

View PDFchevron_right

Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study

Giovanni Luisetto

Journal of Bone and Mineral Research, 2006

View PDFchevron_right

Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals

Gian Ceda

Bone, 2013

View PDFchevron_right

Use of proton pump inhibitors and risk of osteoporosis-related fractures

Colleen Metge

Canadian Medical Association Journal, 2008

View PDFchevron_right

Proton pump inhibitors and fracture risk. The HUNT study, Norway

S. Forsmo

Osteoporosis International, 2019

View PDFchevron_right

Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis

Asif Alam

Osteoporosis International, 2021

View PDFchevron_right

The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density

Mesbah Shams

Risk Management and Healthcare Policy

View PDFchevron_right

Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

Kelly Vogt

Therapeutics and Clinical Risk Management, 2011

View PDFchevron_right

Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis

Seth Richter

Journal of Bone Metabolism, 2018

View PDFchevron_right

Proton-pump inhibitor use and hip fractures in men: a population-based case-control study

jian ZHANG

Annals of Epidemiology, 2014

View PDFchevron_right

Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials

Roberta Navickis

Osteoporosis International, 2010

View PDFchevron_right

Use of proton pump inhibitors and mortality after hip fracture in a nationwide study

Hans Peter Dimai

Osteoporosis International, 2017

View PDFchevron_right

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

Pablo EnrĂ­quez

Osteoporosis International, 2010

View PDFchevron_right

Faculty of 1000 evaluation for Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

John Eisman

F1000 - Post-publication peer review of the biomedical literature

View PDFchevron_right

Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date

Robert Josse

2002

View PDFchevron_right

Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary

Alex Fisher

2010

View PDFchevron_right

Proton pump inhibitors use and change in bone mineral density

Masoud Yavari

International Journal of Rheumatic Diseases, 2016

View PDFchevron_right

Osteoporosis treatment and fracture incidence: the ICARO longitudinal study

G. Luisetto

Osteoporosis International, 2008

View PDFchevron_right

Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis

Holger Gothe

Patient Preference and Adherence, 2008

View PDFchevron_right

The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review

Jonathan Adachi

BMC Musculoskeletal Disorders, 2007

View PDFchevron_right

Concerns on Medications Used in Osteoporosis

Julie Li-Yu

Journal of Clinical Rheumatology and Immunology

View PDFchevron_right

Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative

Shirley Beresford

Journal of the American Geriatrics Society, 2017

View PDFchevron_right

Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence

john sampalis

Journal of Bone and Mineral Research, 2011

View PDFchevron_right

Drug-Related Adverse Events of Osteoporosis Therapy

Moin Khan

View PDFchevron_right

Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004

Suzanne Cadarette

The Journal of rheumatology, 2008

View PDFchevron_right

Osteoporotic hip fractures: Bisphosphonates sales and observed turning point in trend. A population-based retrospective study

Carla Oliveira

Bone, 2013

View PDFchevron_right

Osteoporosis medication and reduced mortality risk in elderly women and men

Jacqueline Center

2011

View PDFchevron_right

Use of Oral Bisphosphonates in Primary Prevention of Fractures in Postmenopausal Women: A Population-Based Cohort Study

Gisela Galindo

PLOS ONE, 2015

View PDFchevron_right

Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study

Suzanne Cadarette

CMAJ open, 2013

View PDFchevron_right

Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy

Leo Massari

Bone, 2013

View PDFchevron_right